Literature DB >> 17921347

Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice.

Leszek Lisowski1, Michel Sadelain.   

Abstract

Globin gene transfer in autologous hematopoietic stem cells is a promising therapeutic option for subjects with beta-thalassemia major. In this approach, high level, erythroid-specific globin transgene expression should correct ineffective erythropoiesis and hemolytic anemia following the delivery of only 1 to 2 vector copies per cell. The generation of vectors that provide high-level globin expression and require low vector copy (VC) integration is therefore essential for both safety and efficacy. We show here the major roles played by 2 lesser-known locus control region elements, termed HS1 and HS4. Partial deletions within HS4 markedly reduce in vivo globin expression requiring multiple VC per cell to correct the anemia. Most strikingly, addition of HS1 to HS2-3-4 increases globin expression by 52%, yielding 9 g Hb/VC in beta-thalassemic mice. Thus, while vectors encoding HS2-3-4 provide curative levels of hemoglobin at 1 to 2 copies per cell, adding HS1 is a promising alternative strategy if upcoming clinical trials prove higher levels of expression to be necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921347      PMCID: PMC2234778          DOI: 10.1182/blood-2007-08-108647

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  A promising genetic approach to the treatment of beta-thalassemia.

Authors:  C May; M Sadelain
Journal:  Trends Cardiovasc Med       Date:  2001-10       Impact factor: 6.677

Review 2.  Locus control regions.

Authors:  Qiliang Li; Kenneth R Peterson; Xiangdong Fang; George Stamatoyannopoulos
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 3.  The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors.

Authors:  Alex H Chang; Michel Sadelain
Journal:  Mol Ther       Date:  2007-01-16       Impact factor: 11.454

4.  The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.

Authors:  Derek A Persons; Phillip W Hargrove; Esther R Allay; Hideki Hanawa; Arthur W Nienhuis
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

5.  Correction of sickle cell disease in transgenic mouse models by gene therapy.

Authors:  R Pawliuk; K A Westerman; M E Fabry; E Payen; R Tighe; E E Bouhassira; S A Acharya; J Ellis; I M London; C J Eaves; R K Humphries; Y Beuzard; R L Nagel; P Leboulch
Journal:  Science       Date:  2001-12-14       Impact factor: 47.728

6.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.

Authors:  C May; S Rivella; J Callegari; G Heller; K M Gaensler; L Luzzatto; M Sadelain
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

7.  Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells.

Authors:  Dana N Levasseur; Thomas M Ryan; Kevin M Pawlik; Tim M Townes
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

8.  Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.

Authors:  Hideki Hanawa; Phillip W Hargrove; Steven Kepes; Deo K Srivastava; Arthur W Nienhuis; Derek A Persons
Journal:  Blood       Date:  2004-06-15       Impact factor: 22.113

Review 9.  Side effects of retroviral gene transfer into hematopoietic stem cells.

Authors:  Christopher Baum; Jochen Düllmann; Zhixiong Li; Boris Fehse; Johann Meyer; David A Williams; Christof von Kalle
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

10.  Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.

Authors:  Suzan Imren; Emmanuel Payen; Karen A Westerman; Robert Pawliuk; Mary E Fabry; Connie J Eaves; Benjamin Cavilla; Louis D Wadsworth; Yves Beuzard; Eric E Bouhassira; Robert Russell; Irving M London; Ronald L Nagel; Philippe Leboulch; R Keith Humphries
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

View more
  26 in total

Review 1.  Pluripotent stem cells in research and treatment of hemoglobinopathies.

Authors:  Natasha Arora; George Q Daley
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.

Authors:  Alisa C Dong; Stefano Rivella
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.

Authors:  Eleni Papanikolaou; Maria Georgomanoli; Evangelos Stamateris; Fottes Panetsos; Markisia Karagiorga; Panagiotis Tsaftaridis; Stelios Graphakos; Nicholas P Anagnou
Journal:  Hum Gene Ther       Date:  2011-12-05       Impact factor: 5.695

Review 4.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

Review 5.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

6.  Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.

Authors:  Farid Boulad; Xiuyan Wang; Jinrong Qu; Clare Taylor; Leda Ferro; Garyfalia Karponi; Shirley Bartido; Patricia Giardina; Glenn Heller; Susan E Prockop; Aurelio Maggio; Michel Sadelain; Isabelle Rivière
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

7.  β-globin gene transfer to human bone marrow for sickle cell disease.

Authors:  Zulema Romero; Fabrizia Urbinati; Sabine Geiger; Aaron R Cooper; Jennifer Wherley; Michael L Kaufman; Roger P Hollis; Rafael Ruiz de Assin; Shantha Senadheera; Arineh Sahagian; Xiangyang Jin; Alyse Gellis; Xiaoyan Wang; David Gjertson; Satiro Deoliveira; Pamela Kempert; Sally Shupien; Hisham Abdel-Azim; Mark C Walters; Herbert J Meiselman; Rosalinda B Wenby; Theresa Gruber; Victor Marder; Thomas D Coates; Donald B Kohn
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

8.  Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.

Authors:  Chang Li; Arpit Suresh Mishra; Sucheol Gil; Meng Wang; Aphrodite Georgakopoulou; Thalia Papayannopoulou; R David Hawkins; André Lieber
Journal:  Mol Ther       Date:  2019-08-19       Impact factor: 11.454

9.  High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells.

Authors:  Hongjie Wang; Zhinan Liu; Chang Li; Sucheol Gil; Thalia Papayannopoulou; Christopher B Doering; André Lieber
Journal:  Blood Adv       Date:  2019-10-08

10.  Complete TCR-α gene locus control region activity in T cells derived in vitro from embryonic stem cells.

Authors:  Armin Lahiji; Martina Kucerová-Levisohn; Jordana Lovett; Roxanne Holmes; Juan Carlos Zúñiga-Pflücker; Benjamin D Ortiz
Journal:  J Immunol       Date:  2013-05-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.